Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cue Biopharma, Inc. (NASDAQ: CUE).

Full DD Report for CUE

You must become a subscriber to view this report.


Recent News from (NASDAQ: CUE)

Cue Biopharma to Host Investor Business Update Call and Webcast
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today t...
Source: GlobeNewswire
Date: May, 10 2018 08:00
Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer
CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancer and autoimmune diseases...
Source: GlobeNewswire
Date: April, 25 2018 08:00
Cue Biopharma to Present at Bloomberg Biotech Innovations Conference
CAMBRIDGE, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it wi...
Source: GlobeNewswire
Date: April, 05 2018 08:00
Cue Biopharma to Present at BIO CEO & Investor Conference
Cue Biopharma ™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be presenting at the BIO CEO & Investo...
Source: Business Wire
Date: February, 07 2018 08:00
Cue Biopharma: Too Early For This Very Exciting Platform
Overview of Company Cue Biopharma is a recent IPO which is looking to address HPV related cancers via interleukin-2 (IL-2), activation of nascent T-cells (not CAR-T) and modulation of autoimmune systems using a novel technology which does not include overall immune suppression. Although the...
Source: SeekingAlpha
Date: February, 06 2018 12:08
U.S. IPO Weekly Recap: IPO Calendar Begins To Fill Up In The First Week Of 2018
A flurry of IPOs joined the calendar to kick off the new year, most notably ADT. Less than two years since Apollo took the security services behemoth private, ADT (ADT) launched a $2 billion public offering that will value the company at $14 billion. After postponing its IPO in 2017, frack...
Source: SeekingAlpha
Date: January, 06 2018 11:18
Cue Biopharma to Provide Corporate Update at the 10th Annual Biotech Showcase 2018 Conference
Cue Biopharma ™, Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be featured as a presenting company at the ...
Source: Business Wire
Date: January, 04 2018 15:00
Cue Biopharma Announces Closing of Initial Public Offering
Cue Biopharma ™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced the closing of its initial public offering of 8,820,710...
Source: Business Wire
Date: January, 02 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1714.3314.2014.7514.17125,498

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-157,77634,24322.7083Cover
2018-08-142,4838,34029.7722Cover
2018-08-132,2934,17454.9353Short
2018-08-108,68018,15647.8079Short
2018-08-099043,67624.5919Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CUE.


About Cue Biopharma, Inc. (NASDAQ: CUE)

Logo for Cue Biopharma, Inc. (NASDAQ: CUE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CUE)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 17 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 29 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 29 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: February, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: CUE)

      Daily Technical Chart for (NASDAQ: CUE)


      Stay tuned for daily updates and more on (NASDAQ: CUE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CUE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CUE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CUE and does not buy, sell, or trade any shares of CUE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/